Dissolution and oral absorption of pranlukast nanosuspensions stabilized by hydroxypropylmethyl cellulose

International Journal of Biological Macromolecules

Volumn 67, Issue , 2014, Pages 53-57

  Baek, In Hwan ^b   Kim, Jung Soo ^c   Ha, Eun Sol ^a   Choo, Gwang Ho ^a   Cho, Wonkyung ^c,d   Hwang, Sung Joo ^d   Kim, Min Soo ^a  

^a Pusan National University   (South Korea)

^b Kyungsung University   (South Korea)

^c Chungnam National University   (South Korea)

^d Yonsei University   (South Korea)

Author keywords

Bioavailability; Nanosuspenion; Pranlukast

Indexed keywords

HYDROXYPROPYLMETHYLCELLULOSE; POLOXAMER; PRANLUKAST; CHROMONE DERIVATIVE; NANOMATERIAL; SUSPENSION;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG SOLUBILITY; DRUG STABILITY; IN VIVO STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MICROEMULSION; MICROFLUIDICS; MICROSUSPENSION; NANOSUSPENSION; NONHUMAN; PARTICLE SIZE; RAT; SOLVENT EXTRACTION; SUSPENSION; ADMINISTRATION AND DOSAGE; CHEMISTRY; DRUG RELEASE; HUMAN; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; CHROMONES; DRUG LIBERATION; HUMANS; HYPROMELLOSE DERIVATIVES; NANOSTRUCTURES; PARTICLE SIZE; SUSPENSIONS;

EID: 84896929571     PISSN: 01418130     EISSN: 18790003     Source Type: Journal    
DOI: 10.1016/j.ijbiomac.2014.03.006     Document Type: Article

References (18)

1. Shegokar R., Müller R.H. Int. J. Pharm. 2010, 399:129-139.
2. Merisko-Liversidge E., Liversidge G.G. Adv. Drug Deliv. Rev. 2011, 63:427-440.
3. Sinha B., Müller R.H., Möschwitzer J.P. Int. J. Pharm. 2013, 453:126-141.
4. Mauludin R., Müller R.H. J. Pharm. Invest. 2013, 43:395-404.
5. Wu Y., Loper A., Landis E., Hettrick L., Novak L., Lynn K., Chen C., Thompson K., Higgins R., Batra U., Shelukar S., Kwei G., Storey D. Int. J. Pharm. 2004, 285:135-146.
6. Jinno J., Kamada N., Miyake M., Yamada K., Mukai T., Odomi M., Toguchi H., Liversidge G.G., Higaki K., Kimura T. J. Control. Release 2006, 111:56-64.
7. Xia D., Cui F., Piao H., Cun D., Piao H., Jiang Y., Ouyang M., Quan P. Pharm. Res. 2010, 27:1965-1976.
8. Sun W., Mao S., Shi Y., Li L.C., Fang L. J. Pharm. Sci. 2011, 100:3365-3373.
9. Kim M.S., Jin S.J., Kim J.S., Park H.J., Song H.S., Neubert R.H., Hwang S.J. Eur. J. Pharm. Biopharm. 2008, 69:454-465.
10. Keam S.J., Lyseng-Williamson K.A., Goa K.L. Drugs 2003, 63:991-1019.
11. Wang L., Hao Y., Liu N., Ma M., Yin Z., Zhang X. Drug Dev. Ind. Pharm. 2012, 38:1381-1389.
12. Chono S., Takeda E., Seki T., Morimoto K. Int. J. Pharm. 2008, 347:71-78.
13. Baek M.K., Lee J.H., Cho Y.H., Kim H.H., Lee G.W. Int. J. Nanomed. 2013, 8:167-176.
14. Dressman J.B., Amidon G.L., Reppas C., Shah V.P. Pharm. Res. 1998, 15:11-22.
15. Müller R.H., Gohla S., Keck C.M. Eur. J. Pharm. Biopharm. 2011, 78:1-9.
16. Durrer C., Irache J.M., Puisieux F., Duchêne D., Ponchel G. Pharm Res. 1994, 11:680-683.
17. Scherer D., Mooren F.C., Kinne R.K., Kreuter J. J. Drug Target. 1993, 1:21-27.
18. Fu Q., Sun J., Ai X., Zhang P., Li M., Wang Y., Liu X., Sun Y., Sui X., Sun L., Han X., Zhu M., Zhang Y., Wang S., He Z. Int. J. Pharm. 2013, 448:290-297.